La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
Hansoh Pharmaceutical Group Gestione
Gestione criteri di controllo 2/4
Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.
Informazioni chiave
Huijuan Zhong
Amministratore delegato
CN¥14.8m
Compenso totale
| Percentuale dello stipendio del CEO | 49.6% |
| Mandato del CEO | 8.8yrs |
| Proprietà del CEO | n/a |
| Durata media del management | 8.5yrs |
| Durata media del Consiglio di amministrazione | 6.9yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Estimating The Fair Value Of Hansoh Pharmaceutical Group Company Limited (HKG:3692)
Aug 28
Pinning Down Hansoh Pharmaceutical Group Company Limited's (HKG:3692) P/E Is Difficult Right Now
Aug 07If EPS Growth Is Important To You, Hansoh Pharmaceutical Group (HKG:3692) Presents An Opportunity
Jul 16Hansoh Pharmaceutical Group (HKG:3692) Could Easily Take On More Debt
Jun 24Hansoh Pharmaceutical Group Company Limited's (HKG:3692) CEO Will Probably Find It Hard To See A Huge Raise This Year
Jun 06Estimating The Intrinsic Value Of Hansoh Pharmaceutical Group Company Limited (HKG:3692)
May 23Hansoh Pharmaceutical Group Company Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
May 01Do Hansoh Pharmaceutical Group's (HKG:3692) Earnings Warrant Your Attention?
Mar 28There's Reason For Concern Over Hansoh Pharmaceutical Group Company Limited's (HKG:3692) Massive 28% Price Jump
Mar 04An Intrinsic Calculation For Hansoh Pharmaceutical Group Company Limited (HKG:3692) Suggests It's 28% Undervalued
Feb 16Hansoh Pharmaceutical Group (HKG:3692) Seems To Use Debt Quite Sensibly
Dec 08Hansoh Pharmaceutical Group Company Limited (HKG:3692) Shares Could Be 25% Below Their Intrinsic Value Estimate
Oct 12Hansoh Pharmaceutical Group's (HKG:3692) Upcoming Dividend Will Be Larger Than Last Year's
Sep 14These 4 Measures Indicate That Hansoh Pharmaceutical Group (HKG:3692) Is Using Debt Reasonably Well
Sep 09Calculating The Intrinsic Value Of Hansoh Pharmaceutical Group Company Limited (HKG:3692)
Jul 10These 4 Measures Indicate That Hansoh Pharmaceutical Group (HKG:3692) Is Using Debt Reasonably Well
Jun 11Calculating The Fair Value Of Hansoh Pharmaceutical Group Company Limited (HKG:3692)
Jan 23Hansoh Pharmaceutical Group (HKG:3692) Has A Rock Solid Balance Sheet
Dec 01Hansoh Pharmaceutical Group Company Limited's (HKG:3692) Intrinsic Value Is Potentially 65% Above Its Share Price
Oct 19Hansoh Pharmaceutical Group (HKG:3692) Could Easily Take On More Debt
Aug 28An Intrinsic Calculation For Hansoh Pharmaceutical Group Company Limited (HKG:3692) Suggests It's 44% Undervalued
Jun 09Hansoh Pharmaceutical Group Company Limited's (HKG:3692) Popularity With Investors Is Under Threat From Overpricing
May 19Is Hansoh Pharmaceutical Group (HKG:3692) A Risky Investment?
Apr 22An Intrinsic Calculation For Hansoh Pharmaceutical Group Company Limited (HKG:3692) Suggests It's 45% Undervalued
Feb 06Hansoh Pharmaceutical Group Company Limited's (HKG:3692) Intrinsic Value Is Potentially 43% Above Its Share Price
Nov 07Hansoh Pharmaceutical Group (HKG:3692) Has A Rock Solid Balance Sheet
Oct 11Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Guadagni aziendali |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | CN¥5b |
| Mar 31 2024 | n/a | n/a | CN¥4b |
| Dec 31 2023 | CN¥15m | CN¥7m | CN¥3b |
| Sep 30 2023 | n/a | n/a | CN¥3b |
| Jun 30 2023 | n/a | n/a | CN¥3b |
| Mar 31 2023 | n/a | n/a | CN¥3b |
| Dec 31 2022 | CN¥11m | CN¥5m | CN¥3b |
| Sep 30 2022 | n/a | n/a | CN¥3b |
| Jun 30 2022 | n/a | n/a | CN¥3b |
| Mar 31 2022 | n/a | n/a | CN¥3b |
| Dec 31 2021 | CN¥16m | CN¥8m | CN¥3b |
Compensazione vs Mercato: La retribuzione totale di Huijuan ($USD 2.07M ) è superiore alla media delle aziende di dimensioni simili nel mercato Hong Kong ($USD 859.20K ).
Compensazione vs guadagni: La retribuzione di Huijuan è aumentata di oltre il 20% nell'ultimo anno.
AMMINISTRATORE DELEGATO
Huijuan Zhong (63 yo)
8.8yrs
Mandato
CN¥14,807,000
Compensazione
Ms. Huijuan Zhong is the Chairlady, Chief Executive Officer, President and Executive Director of Hansoh Pharmaceutical Group Company Limited since December 2, 2015. Ms. Zhong was appointed as a Director of...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Chairlady | 8.8yrs | CN¥14.81m | Nessun dato | |
| Executive Director | 8.5yrs | CN¥9.39m | 0.023% CN¥ 30.0m | |
| Executive Director | 8.8yrs | CN¥16.63m | 0.021% CN¥ 27.0m | |
| VP & CFO | no data | Nessun dato | Nessun dato | |
| Chief of Science Officer | 2.4yrs | Nessun dato | Nessun dato | |
| Senior Vice President | 15.5yrs | Nessun dato | Nessun dato | |
| Chief Commercial Officer | no data | Nessun dato | Nessun dato | |
| Joint Company Secretary & Senior VP | 6.1yrs | Nessun dato | Nessun dato | |
| Joint Company Secretary | less than a year | Nessun dato | Nessun dato |
8.5yrs
Durata media
54.5yo
Età media
Gestione esperta: Il team dirigenziale di 3692 è esperto e expertise (durata media dell'incarico 8.4 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Chairlady | 8.8yrs | CN¥14.81m | Nessun dato | |
| Executive Director | 8.5yrs | CN¥9.39m | 0.023% CN¥ 30.0m | |
| Executive Director | 8.8yrs | CN¥16.63m | 0.021% CN¥ 27.0m | |
| Independent Non-Executive Director | 5.3yrs | CN¥360.00k | Nessun dato | |
| Independent Non-Executive Director | 5.3yrs | CN¥360.00k | Nessun dato | |
| Independent Non-Executive Director | 5.3yrs | CN¥360.00k | Nessun dato |
6.9yrs
Durata media
65yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 3692 sono considerati esperti (durata media dell'incarico 6.8 anni).